[1] Chinese Society of Clinical Oncology (CSCO). Guidelines for Hepatocellular Carcinoma (version 2020)[J]. Beijing, China: People’s Medical Publishing House CoLtd (PMPH), 2020.
[2] Ueshima K, Ogasawara S, Ikeda M, et al: Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma[J]. Liver Cancer,2020,9:583-595.
[3] Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update[J].Liver Cancer,2021,10:181-223.
[4] Jang E S, Yoon J H, Chung J W, et al. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization[J]. J Cancer Res Clin Oncol,2013,139: 635-643.
[5] Xia J, Ren Z, Ye S, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer.[J] Eur J Radiol,2006,59: 407-412.
[6] Woo S, Chung J W, Hur S, et al. Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors[J]. AJR Am J Roentgenol,2013,200: 1370-1377.
[7] Meyer T, Kirkwood A, Roughton M, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma[J]. Br J Cancer,2013,108: 1252-1259.
[8] Pua U, Merkle E M. Case report. Spontaneous cholecystocolic fistula and locoregional liver tumour ablation: a cautionary tale[J]. Br J Radiol,2011,84: e243-e245.
[9] Gu W, Deng X, Lee M, et al. Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids[J]. Nat Med,2021,27(1):115-124. |
